The inhibitory effects of ruxolitinib on the in vitro release of histamine, LTC4, and T2-high cytokines (IL-4 and IL-13) from human basophils suggest that future studies should investigate the safety and efficacy of systemic or topical ruxolitinib in the treatment of the upper and lower airway inflammation. Here, IL4 is linked to inflammation.